Investment Stage

Focus Areas

About Investor

Rob Readnour, Ph.D. is a Managing Director at Mountain Group Partners and serves as a director at AN2 Therapeutics. His investing focus is life sciences and healthcare, particularly pharmaceuticals and diagnostics, typically at Series A and Series B, with a documented investment range of $100K to $5.0M (sweet spot around $1.5M). He brings 30+ years of animal health leadership from Elanco Animal Health, where he led innovation efforts and worked on major acquisitions and early-stage investing partnerships. He holds a Ph.D. in Analytical Chemistry from the University of Illinois.